Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules e-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1

Arthritis and Rheumatism

Volumn 43, Issue 5, 2000, Pages 1085-1093

  Andersen, Grethe Neumann ^a   Caidahl, Kenneth ^b   Kazzam, Elsadig ^a   Petersson, Ann Sofi ^b   Waldenström, Anders ^a   Mincheva Nilsson, Lucia ^a   Rantapää Dahlqvist, Solbritt ^a,c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Department of Rheumatology ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC GMP; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD VESSEL FUNCTION; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; PRIORITY JOURNAL; SKIN BIOPSY; SYSTEMIC SCLEROSIS; URINARY EXCRETION;

AGED; BIOPSY; CELL ADHESION MOLECULES; CYCLIC GMP; CYTOKINES; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, CYTOKINE; SCLERODERMA, SYSTEMIC; SKIN; SOLUBILITY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034049907     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200005)43:5<1085::AID-ANR19>3.0.CO;2-7     Document Type: Article

References (45)

1. Black CM. Systemic sclerosis "state of the art." Scand J Rheumatol 1995;24:194-6.
2. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
3. Kahalch MB. Vascular disease in scleroderma: endothelial T lymphocyte-fibroblast interaction. Rheum Dis Clin North Am 1990;16:53-73.
4. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996;22:675-95.
5. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75:369-76.
6. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am 1996;22:841-60.
7. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
8. Silver RM. Scleroderma: clinical problems. The lungs. Rheum Dis Clin North Am 1996;22:825-40.
9. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22:861-79.
10. Kazzam E, Waldenström A, Landelius J, Hällgren R, Arvidsson A, Caidahl K. Non-invasive assessment of left ventricular diastolic function in patients with systemic sclerosis. J Int Med 1990;228: 183-92.
11. Gustafsson R, Mannting F, Kazzam E, Waldenström A, Hällgren R. Cold-induced reversible myocardial ischaemia in systemic sclerosis. Lancet 1989;2:475-9.
12. Kahalch MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
13. Kazzam E, Waldenström A, Hedner T, Hedner J, Caidahl K. Endothelin may be pathogenic in systemic sclerosis of the heart. Int J Cardiol 1997;60:31-9.
14. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostini A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992;11: 375-82.
15. Denton CP, Bickerstaff MCM, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1948-54.
16. Cook HT, Cattell V. Role of nitric oxide in immune-mediated diseases. Clin Sci (Colch) 1996;91:375-84.
17. Kahaleh B, Fan P-S, Matucci-Cerinic M, Stefanovic-Racic M, Ignarro L. Study of endothelial dependent relaxation in scleroderma [abstract]. Arthritis Rheum 1993;36 Suppl 9:S180.
18. Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998;25:314-7.
19. Kahaleh B, Fan P-S. Down regulation of nitric oxide synthase gene in microvascular endothelial cells from lesional scleroderma: assessment by quantitative RT-PCR and possible role for cytotoxic T-cells (abstract). Arthritis Rheum 1998;41 Suppl 9:S277.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
22. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989;16:328-34.
23. Allen EV, Brown GE. Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 1932;183:187-200.
24. Silman A, Harrison M, Brennan P, and the Ad Hoc International Group on the Assessment of Disease Outcome in Scleroderma. Is it possible to reduce observer variability in skin score assessment of scleroderma? J Rheumatol 1995;22:1277-80.
25. Wennmalm Å, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, et al. Metabolism and excretion of nitric oxide in humans: an experimental and clinical study. Circ Res 1993;73: 1121-7.
26. Hedin L, Gaddy-Kurten D, Kurten R, DeWitt DL, Smith WL, Richards JS. Prostacyclin endoperoxide synthase in rat ovarian follicles: content, cellular distribution and evidence for hormonal induction preceding ovulation. Endocrinology 1987;121:722-31.
27. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis 1996;55:7-20.
28. Carlos T, Kovach N, Schwartz B, Rosa M, Newman B, Wayner E, et al. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 1991;77:2266-71.
29. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-12.
30. Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38:184-9.
31. Shi-Wen X, Panesar M, Vancheeswaran R, Mason J, Haskard D, Black C, et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function - associated antigen 3 by normal and scleroderma fibroblasts: effects of interferon-γ, tumor necrosis factor α, and estrogen. Arthritis Rheum 1994;37:1689-97.
32. Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ. VCAM-1 expression on endothelium in lesions from cutaneous lupus crythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol 1996;135:678-86.
33. Gedeit RG. Tumor necrosis factor-induced E-selectin expression on vascular endothelial cells. Crit Care Med 1996;24:1543-6.
34. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: the Schwartzman phenomenon revisited. Arthritis Rheum 1994;37:376-83.
35. Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, Rediske J, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.
36. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
37. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985;135:3972-7.
38. Gruschwitz MS, Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-γ and tumor necrosis factor α in the early disease stage. Arthritis Rheum 1997;40:540-50.
39. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (II-4), II-10, and II-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32.
40. Kucharz EJ, Brzezinska-Wcislo L, Kotulska A, Gasiorowska-Kielkowska W, Gozdzik J. Elevated serum level of interleukin 10 in patients with systemic sclerosis. Clin Rheumatol 1997;16:638-9.
41. Gruschwitz M, Muller PU, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990;94:197-203.
42. Corrin B, Butcher D, McAnulty BJ, Duhois RM, Black CM, Laurent GJ, et al. Immunohistochemical localization of transforming growth factor-beta I in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-50.
43. Giacomelli R, Cipriani P, Danese C, Pizzuto F, Lattanzio R, Parzanese I, et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin-6, but not transforming growth factor β1. J Rheumatol 1996;23:291-6.
44. Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MIV, Brenchley PEC. Plasma TGFβ in systemic sclerosis: a cross sectional study. Ann Rheum Dis 1994;53:763-7.
45. Wållberg-Jonsson S, Dahlen GH, Nilsson TK, Rånby M, Rantapää-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 1993;12:318-24.